NASDAQ:CYTR LadRx - CYTR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$0.08▼$0.1352-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsHeadlinesSocial Media About LadRx (NASDAQ:CYTR) StockLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Read More Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTR Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comLadRx (NASDAQ:CYTR) Now Covered by Analysts at StockNews.comOctober 5, 2022 | finance.yahoo.comLadRx Corporation Announces OTCQB Ticker Change to LADXMarch 30, 2023 | Porter & Company (Ad)Biden's corruption knows no endPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.September 23, 2022 | finance.yahoo.comCytRx Corporation Relaunches as LadRx CorporationSeptember 8, 2022 | seekingalpha.comEuropean patent office awards CytRx patent for LADR platformSeptember 7, 2022 | finance.yahoo.comEuropean Patent Office Awards CytRx Key PatentAugust 3, 2022 | marketwatch.comTemperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028August 2, 2022 | thestreet.comWhiplash: S&P Veers to All-Time High Before CrashingMarch 30, 2023 | Porter & Company (Ad)Biden's corruption knows no endPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.May 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common StockMay 18, 2022 | marketwatch.comKinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of valueSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryN/A SectorManufacturing Current SymbolNASDAQ:CYTR CUSIPN/A CIKN/A Webwww.cytrx.com Phone(310) 826-5648FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free FloatN/AMarket Cap$4.14 million OptionableNot Optionable BetaN/A Key ExecutivesStephen SnowdyChief Executive OfficerJohn Y. CalozChief Financial Officer, Treasurer & Senior VPFelix KratzVice President-Drug DiscoveryCristina NewmanSecretaryKey CompetitorsAdvisorShares Dorsey Wright Micro-Cap ETFNASDAQ:DWMCLoncar China BioPharma ETFNASDAQ:CHNAInvesco FTSE International Low Beta Equal Weight ETFNASDAQ:IDLBFirst Trust Brazil AlphaDEX FundNASDAQ:FBZFirst Trust IPOX Europe Equity Opportunities ETFNASDAQ:FPXEView All Competitors CYTR Stock - Frequently Asked Questions What is LadRx's stock symbol? LadRx trades on the NASDAQ under the ticker symbol "CYTR." How do I buy shares of LadRx? Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does LadRx make? LadRx (NASDAQ:CYTR) has a market capitalization of $0.00. How can I contact LadRx? LadRx's mailing address is 11726 San Vicente Blvd Ste 650, Los Angeles, California 90049-5079. The official website for the company is www.cytrx.com. The company can be reached via phone at (310) 826-5648. This page (NASDAQ:CYTR) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.